ArticleInternational journal of molecular sciences2018
Topical Administration of Bosentan Prevents Retinal Neurodegeneration in Experimental Diabetes.
Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Association between endothelin-1 and diabetic retinopathy: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Role of NADPH Oxidases as Novel Therapeutic Targets for the Impaired Neurovascular Unit in the Early Stage of Diabetic Retinopathy.International journal of molecular sciences · 2026Review
- Neuroprotection in Diabetes Retinal Disease: An Unmet Medical Need.International journal of molecular sciences · 2026Review
- Recent Investigations on Pathogenesis, Biomarkers, Epigenetics, and Emerging Therapeutic Strategies to Modulate Multiple Signaling Pathways in Diabetic Retinopathy.Journal of ophthalmology · 2026Review
- Diabetes-Driven Retinal Neurodegeneration: Its Role in the Pathogenesis of Diabetic Retinopathy.Biomedicines · 2025Review
- Advances and Perspectives in Relation to the Molecular Basis of Diabetic Retinopathy-A Review.Biomedicines · 2023Review
- What else can we do to prevent diabetic retinopathy?Diabetologia · 2023Article
- New Insights into Treating Early and Advanced Stage Diabetic Retinopathy.International journal of molecular sciences · 2022Review
- Antioxidant Effects of DPP-4 Inhibitors in Early Stages of Experimental Diabetic Retinopathy.Antioxidants (Basel, Switzerland) · 2022Article
- Topical nerve growth factor prevents neurodegenerative and vascular stages of diabetic retinopathy.Frontiers in pharmacology · 2022Article
- Neurovascular Unit: A New Target for Treating Early Stages of Diabetic Retinopathy.Pharmaceutics · 2021Review
- Current understanding of the molecular and cellular pathology of diabetic retinopathy.Nature reviews. Endocrinology · 2021Review
- Effect of Topical Administration of Somatostatin on Retinal Inflammation and Neurodegeneration in an Experimental Model of Diabetes.Journal of clinical medicine · 2020Article
- Genotypic variability in radial resistance to water flow in olive roots and its response to temperature variations.Tree physiology · 2020Article
- Recent Developments in Diabetic Retinal Neurodegeneration: A Literature Review.Journal of diabetes research · 2020Review
- Effect of topical administration of the microneurotrophin BNN27 in the diabetic rat retina.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2019Article
- SOCS1-Derived Peptide Administered by Eye Drops Prevents Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes.International journal of molecular sciences · 2019Article
- Brain Vasculature and Cognition.Arteriosclerosis, thrombosis, and vascular biology · 2019Review
- Relationships Between Neurodegeneration and Vascular Damage in Diabetic Retinopathy.Frontiers in neuroscience · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
Abstract
Experimental evidence suggests that endothelin 1 (ET-1) is involved in the development of retinal microvascular abnormalities induced by diabetes. The effects of ET-1 are mediated by endothelin A- and B-receptors (ETA and ETB). Endothelin B-receptors activation mediates retinal neurodegeneration but there are no data regarding the effectiveness of ETB receptor blockage in arresting retinal neurodegeneration induced by diabetes. The main aim of the present study was to assess the usefulness of topical administration of bosentan (a dual endothelin receptor antagonist) in preventing retinal neurodegeneration in diabetic (db/db) mice. For this purpose, db/db mice aged 10 weeks were treated with one drop of bosentan (5 mg/mL,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.